

Agoraphobia

[View the current Agoraphobia InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Agoraphobia.html>) - Regularly Updated.

Agoraphobia is an anxiety disorder precipitated by the fear of an open or public setting. As a result, sufferers of agoraphobia may avoid these public and/or unfamiliar places. In severe cases, the sufferer may become confined to their home, experiencing difficulty traveling from this "safe place." ([From the Wikipedia article Agoraphobia](#).)

Recent Publications on Agoraphobia:



- [Mechanism of action in CBT \(MAC\): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia.](#)
Cognitive behavioral therapy (CBT) is efficacious for panic disorder with... 13th November, 2009
Dresden University of Technology, Dresden, Germany.- Eur Arch Psychiatry Clin Neurosci. 2009 Nov;259 Suppl 2:S155-66. ([DOI Direct Link](#))
- [A brief Web-based screening questionnaire for common mental disorders: development and validation.](#)
BACKGROUND: The advent of Internet-based self-help systems for common... 24th October, 2009
Department of Clinical Psychology, VU University Amsterdam, Van der- J Med Internet Res. 2009 Jul 24;11(3):e19. ([DOI Direct Link](#))
- [End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients.](#)
OBJECTIVE: Specific psychological withdrawal symptoms following the... 14th October, 2009
Department of Neurology, University of Colorado School of Medicine,- Epilepsy Behav. 2009 Aug;15(4):521-3. Epub 2009 Jul 29. ([DOI Direct Link](#))
- [Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder.](#)
BACKGROUND: Traditional combination strategies of cognitive-behavior... 9th October, 2009
Center for Anxiety and Related Disorders at Boston University, Boston,- Biol Psychiatry. 2009 Oct 5. ([DOI Direct Link](#))
- [Anxiety levels and related pharmacological drug treatment: a memorandum for the third millennium.](#)
Anxiety disorders frequently affect the general population and have a... 6th October, 2009
Dipartimento di Scienze Psichiatriche e Medicina Psicologica, Sapienza- Ann Ist Super Sanita. 2009;45(2):193-204.
- [Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire \(4DSQ\) and the Hospital Anxiety and Depression Scale \(HADS\).](#)
BACKGROUND: Depressive and anxiety disorders often go unrecognized in... 3rd October, 2009
Department of General Practice, EMGO Institute for Health and Care- BMC Fam Pract. 2009 Aug 23;10:58. ([DOI Direct Link](#))
- [Psychological treatment of panic disorder with or without agoraphobia: A meta-analysis.](#)

- Although the efficacy of psychological treatment for panic disorder (PD)...*25th September, 2009
University of Murcia, Spain.- Clin Psychol Rev. 2009 Sep 3. ([DOI Direct Link](#))
- [Genetic and environmental influences on the co-morbidity between depression, panic disorder, agoraphobia, and social phobia: a twin study.](#)
*BACKGROUND: Major depression (MD) and anxiety disorders such as panic...*15th September, 2009
Queensland Institute of Medical Research, Brisbane, QLD 4029, Australia.- Depress Anxiety. 2009;26(11):1004-11. ([DOI Direct Link](#))
 - [Atypical depression: useful concept, but it's time to revise the DSM-IV criteria.](#)
*Stewart et al (2009) have outlined the evidence in support of the validity...*11th September, 2009
Department of Psychiatry, University of Pennsylvania School of Medicine- Neuropsychopharmacology. 2009 Dec;34(13):2633-41. Epub 2009 Sep 9. ([DOI Direct Link](#))
 - [Development of mental health first aid guidelines for panic attacks: a Delphi study.](#)
*BACKGROUND: Panic attacks are common, and while they are not...*11th September, 2009
ORYGEN Research Centre, University of Melbourne, Australia.- BMC Psychiatry. 2009 Aug 10;9:49. ([DOI Direct Link](#))
 - [Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.](#)
*This review summarizes findings on the epidemiology and etiology of...*1st September, 2009
Institute of Clinical Psychology and Psychotherapy, Department of- Psychiatr Clin North Am. 2009 Sep;32(3):483-524. ([DOI Direct Link](#))
 - [A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up.](#)
*A randomized controlled clinical trial with a wait-list control group was...*28th August, 2009
Universite du Quebec a Montreal and Centre de Recherche Fernand-Seguin,- J Anxiety Disord. 2009 Dec;23(8):1139-47. Epub 2009 Aug 6. ([DOI Direct Link](#))
 - [Reliving and disorganization in posttraumatic stress disorder and panic disorder memories.](#)
*Intense, disorganized recollections are one of the core symptoms of...*21st August, 2009
Department of Clinical, Health, and Neuropsychology, Leiden University,- J Nerv Ment Dis. 2009 Aug;197(8):627-30. ([DOI Direct Link](#))
 - [The impact of differing anxiety disorders on outcome following an acute coronary syndrome: time to start worrying?](#)
*Background: Both depression and anxiety have been implicated as...*20th August, 2009
School of Psychiatry, University of New South Wales, Kensington, Sydney,- Depress Anxiety. 2009 Aug 18. ([DOI Direct Link](#))
 - [\[A clinical trap: acute and chronic psychogenic dyspnea\]](#)
*Psychogenic dyspnea may be part of two main clinical pictures. The first...*6th August, 2009
Psychiatre honoraire des hopitaux, charge de cours a l'universite Lyon-1,- Rev Prat. 2009 May 20;59(5):615-8.

BioNews Results for Agoraphobia

- [Depressed teens 'at higher risk of mental health problems in later life'](#)
Webindia123: Sep 2 2009 10:59AM Matching: agoraphobia

Agoraphobia Clinical Trials:



- [Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia](#)

Agoraphobia Patents:



- 7531541- [Partial mGluR5 antagonists for treatment of anxiety and CNS disorders](#)
- 7553866- [Thiolactones](#)
- 7560058- [Magnetic core for medical procedures](#)
- 7560562- [Piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors](#)
- 7563797- [Substituted imidazo\(1,2-A\)pyrimidines and imidazo\(1,2-A\) pyridines as cannabinoid receptor ligands](#)
- 7563908- [2-\(1H-indolylsulfanyl\)-benzyl amine derivatives as SSRI](#)
- 7566709- [1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders](#)
- 7566725- [Imidazo\[1,2-A\] pyridine anxiolytics](#)
- 7566735- [Compounds which potentiate AMPA receptor and uses thereof in medicine](#)
- 7569605- [Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion](#)
- 7572786- [Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists](#)
- 7550482- [Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors](#)
- 7550469- [Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands](#)
- 7550465- [Pyrido\[3,2-e\]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them](#)
- 7531572- [Acyloxyalkyl carbamate prodrugs of .alpha.-amino acids, methods of synthesis and use](#)
- 7534791- [Benzo\[b\]furane and benzo\[b\]thiophene derivatives](#)
- 7534859- [Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse](#)
- 7534893- [Imidazol-2-one compounds useful in the treatment of various disorders](#)
- 7538106- [Application of 2-cyano-10- \(2-methyl-3- \(methylamino\)- propyl\) phenothiazine or a pharmaceutically acceptable salt as medicament](#)
- 7538114- [Glycine transporter-1 inhibitors](#)
- 7538123- [Indole derivative having piperidine ring](#)
- 7544694- [Substituted diaza-spiro-\[5.5\]-undecane derivatives and their use as neurokinin antagonists](#)
- 7544815- [Process for making hydroisoindoline tachykinin receptor antagonists](#)
- 7547788- [Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors](#)
- 7572792- [Azetidine glycine transporter inhibitors](#)

- 7572812- [Therapeutic agents useful for treating pain](#)
- 7598423- [Potentiators of glutamate receptors](#)
- 7601115- [Seizure therapy method and apparatus](#)
- 7601756- [Method of treatment for irritable bowel syndrome](#)
- 7601870- [Substituted aniline derivatives](#)
- 7608626- [Substituted indolizines and derivatives as CNS agents](#)
- 7612056- [Substituted diaza-spiro-\[4.5\]-decane derivatives and their use as neurokinin antagonists](#)
- 7612078- [Piperidinylamino-thieno\[2,3-D\] pyrimidine compounds](#)
- 7618958- [Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects](#)
- 7618967- [Indane compounds](#)
- 7618969- [Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- 7595340- [Serotonin and norepinephrine reuptake inhibitor and uses thereof](#)
- 7592346- [Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors](#)
- 7589237- [Treatment of CNS disorders with trans 4-\(3,4-dichlorophenyl\)-1,2,3,4-tetrahydro-1-naphthalenamine](#)
- 7572819- [Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- 7572822- [Biaryl substituted triazoles as sodium channel blockers](#)
- 7576081- [Morpholine dopamine agonists](#)
- 7576083- [Morpholinyl piperidine glycine transporter inhibitors](#)
- 7576211- [Synthesis of thienopyridinone compounds and related intermediates](#)
- 7579370- [Fused heterocycles](#)
- 7582635- [Therapeutic agents useful for treating pain](#)
- 7585996- [Acyloxyalkyl carbamate prodrugs, methods of synthesis and use](#)
- 7589116- [Biaryl substituted pyrazoles as sodium channel blockers](#)
- 7589206- [Pyrrolopyridine derivatives](#)
- 7619110- [Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

